Antenatal screening for chromosomal abnormalities
US6010912A · kind A · utility
Assignee
Inventor
Key dates
| Filing date | Dec 4, 1995 |
| Grant date | Jan 4, 2000 |
| Priority date | — |
| Expiry date | Dec 4, 2015 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S436/818
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
A method for antenatal screening for chromosomal abnormalities in which maternal blood from a pregnant woman is measured for levels of free beta hCG and at least a second serum marker and/or precursors and metabolites of these markers and the measured levels of these markers together with the gestational age of the pregnant woman are compared to reference values at various gestational ages of the levels for free beta hCG and the second serum marker in (a) pregnant women carrying foetuses having the abnormalitie(s) subject to the screen and (b) pregnant women carrying normal foetuses, the comparison being indicative of the risk of the pregnant woman carrying a foetus with an abnormality subject to the screen characterised in that the second serum marker is pregnancy associated plasma protein A (PAPPA) and the screen is carried out by the end of the thirteenth (13th) completed week of pregnancy.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.